HWKN · NASDAQ
Average $177.74 (+35.7% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| Barclays | Oct 13, 2026 | Maintains | Equal-Weight |
| BWS Financial | Aug 3, 2026 | Maintains | Buy |
| Barclays | Jul 31, 2026 | Maintains | Equal-Weight |
| Barclays | Jun 30, 2026 | Initiates | Equal-Weight |
| BWS Financial | Mar 23, 2026 | Maintains | Buy |
| BWS Financial | Jan 29, 2026 | Maintains | Buy |
| BWS Financial | Nov 3, 2025 | Maintains | Buy |
Updated Jul 21, 2026
Hawkins is a specialty chemicals company with three distinct segments including industrial, water treatment, and food and health sciences, with a history of benefiting from inventory and supply chain volatility. Despite a sales miss in the fiscal third quarter, upcoming events such as the Iran War may provide an opportunity for strong sales performance in the fiscal fourth and first quarters.
Hawkins is expected to see an increase in sales in the months of March and April due to the backlog in global trade, giving them an advantage in the domestic market, as well as a potential opportunity to maximize their inventory during this time. However, the supply chain interruptions caused by the Iran War may have negative impacts on the company's fiscal year-end results, which are not reported until the second half of May. Furthermore, the company's focus on specialty chemicals may also make it vulnerable to fluctuating market conditions and competition.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
